Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions
- Conditions
- PharmacokineticsDrug Interactions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 17
- Registration Number
- NCT05433896
- Locations
- 🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States
A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05392127
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 112
- Registration Number
- NCT05342532
- Locations
- 🇺🇸
Mount Sinai Union Square Division of Digestive Diseases, New York, New York, United States
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT05338502
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319912
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05273775
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 45
- Registration Number
- NCT05264142
- Locations
- 🇨🇭
Geneva University Hospitals, HUG, Genève, Switzerland
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
- Conditions
- Knee, Osteoarthritis (OA)Biomarkers for Prediction of OA Treatment Efficacy
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 17
- Registration Number
- NCT05256342
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05254548
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.